Senores Pharmaceuticals to acquire Apnar Pharma for ₹91 crore

• Senores Pharmaceuticals to acquire 100% equity stake in Apnar Pharma Private Ltd.
• The acquisition is valued at an enterprise value of ₹91 crore.
• Apnar Pharma manufactures generic pharmaceutical formulations and operates a USFDA, UK-MHRA, and Health Canada approved facility.
• The transaction will be completed in two tranches, with the first by March 2026 and the second by Q2 FY27.

Why It Matters: Senores Pharma expands global reach with Apnar Pharma acquisition.